• +1-646-491-9876
    • +91-20-67278686

    Search

    Human Papillomavirus Minor Capsid Protein L2-Pipeline Review H1 2017

    Human Papillomavirus Minor Capsid Protein L2-Pipeline Review H1 2017

    • Report Code ID: RW0001834436
    • Category Pharmaceuticals
    • No. of Pages 30
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H1 2017

    Summary

    According to the recently published report 'Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H1 2017'; Human Papillomavirus Minor Capsid Protein L2 (L2) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

    Human Papillomavirus Minor Capsid Protein L2 (L2) - L2 is a minor capsid component and lacks the capacity to form VLPs. This protein plays a role in capsid stabilization through interaction with the major capsid protein L1. It also plays a role through its interaction with host dynein in the intracellular microtubule-dependent transport of viral capsid toward the nucleus. It mediates the viral genome import into the nucleus through binding to host importins.

    The report 'Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H1 2017' outlays comprehensive information on the Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviewsalso reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Cervical Cancer, Human Papillomavirus (HPV) Associated Cancer, Human Papillomavirus Infections, Genital Warts (Condylomata Acuminata) and Warts.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Minor Capsid Protein L2 (L2)
    - The report reviews Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Human Papillomavirus Minor Capsid Protein L2 (L2)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Human Papillomavirus Minor Capsid Protein L2 (L2) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Human Papillomavirus Minor Capsid Protein L2 (L2) - Overview
    Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Assessment
    Assessment by Route of Administration
    Assessment by Molecule Type
    Human Papillomavirus Minor Capsid Protein L2 (L2) - Companies Involved in Therapeutics Development
    Agilvax Inc
    Cancer Research Technology Ltd
    Pathovax LLC
    Human Papillomavirus Minor Capsid Protein L2 (L2) - Drug Profiles
    AX-03 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PVX-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RGVax - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TA-CIN - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Human Papillomavirus Minor Capsid Protein L2 (L2) - Dormant Products
    Human Papillomavirus Minor Capsid Protein L2 (L2) - Product Development Milestones
    Featured News & Press Releases
    Oct 27, 2016: PathoVax Wins $500,000 in 43North Contest
    Sep 06, 2016: Agilvax Receives New Patent for Its Cost-Effective Broadly Protective HPV Vaccine Candidate
    Feb 03, 2015: Agilvax Is Advancing Clinical Production of its Lead Vaccine Against Human Papillomavirus
    Oct 30, 2014: National Cancer Institute supports next-generation Austrian HPV vaccine
    Sep 10, 2013: New, Even More Effective HPV Vaccine In Sight
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Agilvax Inc, H1 2017
    Pipeline by Cancer Research Technology Ltd, H1 2017
    Pipeline by Pathovax LLC, H1 2017
    Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Agilvax Inc
    Cancer Research Technology Ltd
    Pathovax LLC

    Request for Sample

    Report Url http://www.reportsweb.com//human-papillomavirus-minor-capsid-protein-l2-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//human-papillomavirus-minor-capsid-protein-l2-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//human-papillomavirus-minor-capsid-protein-l2-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments